Literature DB >> 2804551

Functional and binding studies with muscarinic M2-subtype selective antagonists.

S Lazareno1, F F Roberts.   

Abstract

1. The potency of a series of selective muscarinic antagonists has been measured on two functional isolated tissue preparations (rat ileum and atria) and these compared with their potency on a range of binding preparations in order to determine whether the subtypes of M2 receptor measured functionally are the same as those measured in binding studies. 2. On the functional preparations pirenzepine, hexahydrosiladiphenidol (HSD) and 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) were more potent on the ileum than on the atrium (3 fold, 29 fold and 5 fold respectively), whereas himbacine, AF-DX 116 and methoctramine showed the opposite selectivity (5 fold, 3 fold and 56 fold respectively). Atropine had a similar potency on the ileum and atrium. 3. [3H]-N-methyl scopolamine was used to study M2 binding sites on membranes from rat heart and rat submandibular gland. Each preparation appeared to contain a homogeneous binding site population. The potencies of the five M2 selective antagonists (and pirenzepine) in binding studies to heart membranes were very similar to those observed in functional studies of rat atria (correlation coefficient = 0.98). Similarly the binding to submandibular gland membranes was very similar to that observed in functional studies on rat ileum (correlation coefficient = 0.97). 4. [3H]-pirenzepine was used to examine the binding of these antagonists to M1 binding sites on membranes from rat cerebral cortex. The affinities of 4-DAMP, HSD, AF-DX116 and himbacine at M1 sites were similar to their affinities on the gland. Only pirenzepine and methoctramine had higher affinity on M1 sites than on the gland. 5. Himbacine had a 20 fold lower affinity at M1 binding sites than at heart sites, and it should therefore be an important tool in identifying M1 sites. 6. Inhibition of [3H]-N-methyl scopolamine binding to rat ileum and rat brainstem by M2-selective antagonists was best described by a two-site model. In both cases the major population of sites (70-90%) appeared to be similar to sites found on the heart (correlation coefficients = 0.95 and 0.97). The other site appeared to be similar to that on the submandibular gland (correlation coefficients = 0.96 and 1.00). 7. The correlations observed in these studies in which a range of selective muscarinic antagonists was used lend weight to previous studies indicating the presence of three functionally important muscarinic receptor subtypes, typified by the binding sites studied in the cerebral cortex, submandibular gland and heart. 8. We propose that the sub-classification of the M2 muscarinic receptor into M2 and M3 subtypes on the basis of ligand binding studies should be extended to cover functionally-defined receptors as well.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804551      PMCID: PMC1854657          DOI: 10.1111/j.1476-5381.1989.tb16896.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Methoctramine reveals heterogeneity of M2 muscarinic receptors in longitudinal ileal smooth muscle membranes.

Authors:  A D Michel; R L Whiting
Journal:  Eur J Pharmacol       Date:  1988-01-19       Impact factor: 4.432

Review 2.  Muscarinic receptor heterogeneity in smooth muscle: binding and functional studies with AF-DX 116.

Authors:  H Ladinsky; E Giraldo; E Monferini; G B Schiavi; M A Viganò; L De Conti; R Micheletti; R Hammer
Journal:  Trends Pharmacol Sci       Date:  1988-02       Impact factor: 14.819

3.  Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes.

Authors:  A Maeda; T Kubo; M Mishina; S Numa
Journal:  FEBS Lett       Date:  1988-11-07       Impact factor: 4.124

Review 4.  Muscarinic receptor differentiation.

Authors:  F Mitchelson
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

5.  Localization of a family of muscarinic receptor mRNAs in rat brain.

Authors:  N J Buckley; T I Bonner; M R Brann
Journal:  J Neurosci       Date:  1988-12       Impact factor: 6.167

6.  Himbacine recognizes a high affinity subtype of M2 muscarinic cholinergic receptors in the rat cerebral cortex.

Authors:  J X Wang; W R Roeske; W Wang; H I Yamamura
Journal:  Brain Res       Date:  1988-04-12       Impact factor: 3.252

7.  Characterization of the muscarinic receptor subtypes in the rat urinary bladder.

Authors:  E Monferini; E Giraldo; H Ladinsky
Journal:  Eur J Pharmacol       Date:  1988-03-15       Impact factor: 4.432

8.  Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine.

Authors:  C Melchiorre; P Angeli; G Lambrecht; E Mutschler; M T Picchio; J Wess
Journal:  Eur J Pharmacol       Date:  1987-12-01       Impact factor: 4.432

9.  Binding and functional characterization of the cardioselective muscarinic antagonist methoctramine.

Authors:  E Giraldo; R Micheletti; E Montagna; A Giachetti; M A Viganò; H Ladinsky; C Melchiorre
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

10.  Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors.

Authors:  E G Peralta; A Ashkenazi; J W Winslow; D H Smith; J Ramachandran; D J Capon
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

View more
  18 in total

1.  Characterization of pre- and postsynaptic muscarinic receptors in circular muscle of pig gastric fundus.

Authors:  Pascal G Leclere; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart.

Authors:  E W Larson; M A Pfenning; E Richelson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Distinct muscarinic receptors inhibit release of gamma-aminobutyric acid and excitatory amino acids in mammalian brain.

Authors:  S Sugita; N Uchimura; Z G Jiang; R A North
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation.

Authors:  Monika Maier-Peuschel; Nadine Frölich; Christian Dees; Leif G Hommers; Carsten Hoffmann; Viacheslav O Nikolaev; Martin J Lohse
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

5.  Increased function of inhibitory neuronal M2 muscarinic receptors in trachea and ileum of diabetic rats.

Authors:  Fiona R Coulson; David B Jacoby; Allison D Fryer
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Pharmacology of the putative M4 muscarinic receptor mediating Ca-current inhibition in neuroblastoma x glioma hybrid (NG 108-15) cells.

Authors:  M P Caulfield; D A Brown
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

7.  Interaction of selective compounds with muscarinic receptors at dispersed intestinal smooth muscle cells.

Authors:  E Barocelli; M Chiavarini; V Ballabeni; F Bordi; M Impicciatore
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  Subtype-selective blockade of cardiac muscarinic receptors inhibits vagal chronotropic responses in cats.

Authors:  Oleg E Osadchii
Journal:  Pflugers Arch       Date:  2007-09-25       Impact factor: 3.657

9.  Novel pharmacological profile of muscarinic receptors mediating contraction of the guinea-pig uterus.

Authors:  F Dörje; T Friebe; R Tacke; E Mutschler; G Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

10.  The cholinomimetic agent bethanechol activates IK(ACh) in feline atrial myocytes.

Authors:  Dora E Benavides-Haro; Ricardo A Navarro-Polanco; José A Sánchez-Chapula
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.